Evidence-based studies show that angiogenesis-dependent VEGF inhibition is the most relevant therapy for combating the cancer disease, which has resulted in the development of several anti-VEGF agents by targeting the VEGF pathway (e.g., aflibercept), VEGF receptors (e.g., ramucirumab) and the inhibition of tyrosine kinase signaling [22]. This evidence concerns the gene VEGFA and cancer.